ABSTRACT
Background: In Ayurveda all the skin diseases are described under the term Kushtha which is mentioned as a Raktapradoshaja vikara. Due to Rakta dusti several disease pathogenesis accurse in population which leads to Raktapradoshaja vikara.Methods: Present study aimed to conduct a cross-sectional survey based study for investigating the role of Raktapradoshaja nidana in the pathogenesis Kushtha (skin diseases). A duly prepared proforma was prepared based on various etiology of Raktapradoshaja vikara mentioned in classical texts of Ayurveda. Total 500 patients diagnosed as skin disease were screened on the basis of prepared questionnaires prior obtaining the ethical clearance form IEC, NIA, Jaipur (IEC/ACA/2017/60 dated 26/04/2017).Results: Based on over all observation the present survey study explains an easy diagnostic criterion for the different types of Raktapradoshaja vikara mentioned in Ayurveda. Here a unique attempt was taken for quantitative analysis of various classical nidana in relation to the pathogenesis of the disease Raktapradoshaja vikara.Conclusions: Analyzed data of all these extreme exposure of nidana may provide a significant role for diagnosis, prognosis, as well as prevention of the disease of Raktapradoshaja vikara.
ABSTRACT
In essential hypertension, mainly Vata prakopa occurs, particularly Vyana vata as it is responsible for Rasa- rakta samvahana. By virtue of its Ruksha, Sheeta and Khara guna, Rasa-rakta vahini dhamanis are constricted, also its Ruksha guna dries the Malarupa kapha at the inner side of the vessels making them more rigid (Kathin). Vascular lumen may be reduced further leading to obstruction in it. So, for normal circulatory function, increased force of Vyana vayu is required resulting into Vyana bala Vaishamya and hence leading to the development of hypertension. The WHO rates hypertension as one of the most important causes of premature death worldwide. Worldwide, approximately 1 billion people have hypertension, contributing to more than 7.1 million deaths per year. The number of adults with hypertension in 2025 is predicted to increase by about 60% to a total of around 1.56 billion. In India, Cardiovascular diseases caused 2.3 million deaths in the year 1990; this is projected to double by the year 2020. Numbers of drugs are available in modern medicine to treat the disease in its symptomatically active state but still are unable to cure the hypertension. Hyper function of Vyana is considered under Vyana Bala Vaishamya which produces increased force in the wall of the channels (blood vessels) to produce the disease hypertension. In the present clinical trial ‘Punarnava Churna’ is orally administered for 1 month twice a day after food. 30 clinically diagnosed patients of hypertension were randomly selected and divided into two groups. BP, CBC, RBS, ECG, Blood urea, Serum creatinine and Lipid profile were done before and after the clinical trial. After completion of study signs and symptoms were controlled significantly and also there were significant changes in laboratory findings.